Asymmetric sensorineural hearing loss is a risk factor for late‐onset hearing loss in pediatric cancer survivors following cisplatin treatment

Abstract

Children receiving cisplatin therapy are at risk for developing AHL and LOHL. Those that have received radiation and/or with AHL are at increased risk for further hearing decline. Long-term monitoring of these patients is important for early intervention as hearing diminishes.